We evaluated the potential for these genes as prognostic markers and therapeutic targets using ectopic overexpression of H3F3A and an LPA antagonist, which inhibits GPR87. Our results indicate that using H3F3A as a prognostic marker and GPR87 as a therapeutic target is a promising lung cancer treatment strategy. This evidence concerns the gene LPA and lung cancer.